Adaptive Biotechnologies President and Chief Operating Officer Julie Rubinstein sold 35,643 shares of the company’s common stock for a total of $928,891 in transactions from October 30 to November 3, 2026. The sales followed the exercise of options to acquire the same number of shares at $12.14 each, with a reported total value of $432,706.
On October 30, Rubinstein exercised options for 11,881 shares and sold those shares in two groups: 9,486 at prices ranging from $26.20 to $27.07, and 2,395 at prices between $27.21 and $27.98. On November 2, she exercised options for another 11,881 shares at $12.14 each and sold 9,296 shares for between $24.88 and $25.86, plus 2,585 shares for between $25.91 and $26.81.
The final reported transactions took place on November 3, when Rubinstein exercised options for 11,881 shares at $12.14 each and sold 11,881 shares at prices ranging from $25.65 to $26.43. The filing states that all transactions were made under a Rule 10b5-1 trading plan adopted on November 18, 2025. After the transactions, Rubinstein directly held 377,802 shares.
The stock had risen 78% over the previous six months, according to the source report. It also reported a share price of $25.80 and a market capitalization of $4 billion. The report noted that InvestingPro’s analysis assessed the shares as trading above its fair value.
Sources: Investing.com News.